Logo Logo Logo Logo Logo

Investor portal

  • About Droia
  • Portfolio
  • People
  • News
  • Careers
  • Contact
  • About Droia
  • Portfolio
  • People
  • News
  • Careers
  • Contact
  • Investor portal

06 Dec Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies

Posted at 15:05h in Hummingbird Bioscience
Share

Hummingbird Bioscience and Cancer Research UK today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013)....

Read More

29 Nov Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board

Posted at 15:12h in Hummingbird Bioscience
Share

I am delighted to welcome Jan to Hummingbird’s Board of Directors as our Chairman. His extensive experience leading and scaling businesses spanning from drug discovery to commercial stage companies is invaluable to Hummingbird Bioscience, as we chart our next stage of growth and pursue our...

Read More

18 May Hummingbird Bioscience Raises US$125 Million in Series C Financing

Posted at 14:02h in Hummingbird Bioscience
Share

“We are delighted to have the support and confidence of leading global healthcare investors to advance the development of our unique pipeline of precision therapies against important, yet hard-to-drug targets. We have made tremendous progress since closing our Series B in 2019 and this financing...

Read More
Droia ventures

DROIA SA (LUX)  |  DROIA VENTURES (BE)
contact@droiaventures.com

ESG Disclosures

© DROIA — website made by design